Pulmonx cuts FY25 revenue view to $90M-$92M from $96M-$98M, consensus $96.95M

The company said, “Pulmonx (LUNG) is revising full year 2025 revenue guidance to be in the range of $90 million to $92 million, anticipating a trajectory slightly lower than its prior expectations of $96 million to $98 million. The Company expects gross margin for the full year 2025 to be approximately 74%. Pulmonx is also revising its total operating expenses for the full year 2025 to fall within the range of $128 million to $130 million, a decrease from prior guidance of $133 million to $135 million, inclusive of approximately $22 million of non-cash stock-based compensation. The Company’s updated guidance does not anticipate any potential impact from future tariffs or trade policy changes, or their effects on the global macroeconomic environment, including foreign currency fluctuations.”